SCHEMBL508929

SCHEMBL508929

[2H]C([2H])([2H])C([2H])(Br)C([2H])([2H])[2H]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12691708 0.82
SCHEMBL30507223 0.76
SCHEMBL18170424 0.67
Bromoform SCHEMBL30113935 0.61
Isobutane SCHEMBL30203183 0.55
Isopropyl Alcohol SCHEMBL1955704 0.55
Isobutane SCHEMBL29666472 0.53
SCHEMBL1803530 0.53
SCHEMBL4352 0.49
Bromomethane SCHEMBL13032077 0.49

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025128873-A1 HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
WO-2025067457-A1 HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-04-03 WO disclosed
EP-3603674-B1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN SUN PHARMACEUTICAL IND INC (US) 2025-02-26 EP disclosed
US-20230285387-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY CONCERT PHARMACEUTICALS, INC. 2023-09-14 US disclosed
US-20220023292-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY CONCERT PHARMACEUTICALS, INC. 2022-01-27 US disclosed
US-10813926-B2 Morphinan compounds CONCERT PHARMACEUTICALS, INC. (US) 2020-10-27 US disclosed
EP-3603674-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN CONCERT PHARMACEUTICALS, INC. (US) 2020-02-05 EP disclosed
US-10406155-B2 Morphinan compounds CONCERT PHARMACEUTICALS, INC. (US) 2019-09-10 US disclosed
EP-3248978-B1 DEUTERATED MORPHINAN COMPOUNDS CONCERT PHARMACEUTICALS INC (US) 2019-08-07 EP disclosed
US-20190038618-A1 MORPHINAN COMPOUNDS SUN PHARMACEUTICAL INDUSTRIES, INC. 2019-02-07 US disclosed
EP-2634187-A1 Deuterated morphinane compounds Concert Pharmaceuticals Inc. (US) 2013-09-04 EP disclosed
EP-2334678-B1 MORPHINAN COMPOUNDS CONCERT PHARMACEUTICALS INC (US) 2012-12-26 EP disclosed
US-20120244122-A1 Peptides for the Treatment of HCV Infections CONCERT PHARMACEUTICALS, INC. 2012-09-27 US disclosed
US-20120083487-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY CONCERT PHARMACEUTICALS, INC. 2012-04-05 US disclosed
EP-2418211-A1 Deuterated morphinane compounds Concert Pharmaceuticals Inc. (US) 2012-02-15 EP disclosed
US-20120029007-A1 MORPHINAN COMPOUNDS CONCERT PHARMACEUTICALS INC. 2012-02-02 US disclosed
EP-2397158-A2 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect CONCERT PHARMACEUTICALS, INC. (US) 2011-12-21 EP disclosed
US-20110257214-A1 MORPHINAN COMPOUNDS SUN PHARMACEUTICAL INDUSTRIES, INC. 2011-10-20 US disclosed
WO-2010138889-A1 PEPTIDES FOR THE TREATMENT OF HCV INFECTIONS CONCERT PHARMACEUTICALS, INC. (US) 2010-12-02 WO disclosed
US-20090175824-A1 Peptides for the treatment of HCV infections CONCERT PHARMACEUTICALS, INC. 2009-07-09 US disclosed